Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions

Inclusion Criteria: Were in the age range of 18-45 years. * Were neither overweight nor underweight for his height as per the Life Insurance Corporation of India height/weight chart for non-medical cases. * Had voluntarily given written informed consent to participate in this study. * Had a non-vegetarian diet habit. * Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study. Exclusion Criteria: History of allergy or hypersensitivity to Ondansetron, related drugs or any other serotonin receptor blocker drugs * History of hiccups * History of urticarial reaction, rash on exposure to any drug. * History of anaphylaxis, angina, seizures, extrapyramidal symptoms, recent history of dizziness. * History of recurrent episodes of headache. * History of hepatitis, phenylketonuria, recent history of constipation. * History of bronchospasm, asthma, shortness of breath. * Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations. * Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection. * Presence of values which were significantly different from normal reference ranges and/or judged clinically significant for haemoglobin, total white blood cells count, differential WBC count or platelet count. * Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids) * Presence of values which were significantly different from normal reference ranges and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol. * Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (\> 4/HPF), epithelial cells (\> 4/HPF), glucose (positive) or protein (positive). * Clinically abnormal ECG or Chest X-ray. * History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma. * History of any psychiatric illness, which might impair the ability to provide written informed consent. * Regular smokers who smoked more than 10 cigarettes daily or had difficulty abstaining from smoking for the duration of each study period. * History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period. * Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study. * Participation in any clinical trial within 12 weeks preceding Day 1 of this study. * Subjects who, through completion of this study, would have donated and/or lost more than 350 mL of blood in the past 3 months.